Chinese herbal medicine for impaired glucose tolerance: A randomized placebo controlled trial

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Grant, Suzanne J ^a   Chang, Dennis Hsu Tung ^a   Liu, Jianxun ^b   Wong, Vincent ^c   Kiat, Hosen ^d   Bensoussan, Alan ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b XIYUAN HOSPITAL   (China)

^c SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHINESE DRUG; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; JIANTANG XIAOZHI; LIPID; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; BLOOD PRESSURE; BODY MASS; CHINESE MEDICINE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HERBAL MEDICINE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT DURATION; WAIST CIRCUMFERENCE; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; METABOLISM; MIDDLE AGED; PHYTOTHERAPY; POSTPRANDIAL STATE; PREDIABETIC STATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHYTOTHERAPY; POSTPRANDIAL PERIOD; PREDIABETIC STATE;

EID: 84877910332     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-104     Document Type: Article

References (37)

1. International Diabetes Federation IDFDiabetes Atlas 2007, Brussels, Belgium: International Diabetes Federation, 3, http://www.idf.org/diabetesatlas, International Diabetes Federation.
2. Barr E, Cameron A, Balkau B, Zimmet P, Welborn T, Tonkin A, Shaw J. HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the australian diabetes, obesity and lifestyle study (AusDiab) study. Diabetologia 2009,
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22(2):233-240. 10.2337/diacare.22.2.233, 10333939.
4. Gerstein HC. Fasting versus postload glucose levels. Diabetes Care 2001, 24(11):1855-1857. 10.2337/diacare.24.11.1855, 11679446.
5. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355(23):2427-2443. 10.1056/NEJMoa066224, 17145742.
6. Egede LE, Ye X, Zheng D, Silverstein MD. The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care 2002, 25(2):324-329. 10.2337/diacare.25.2.324, 11815504.
7. Grant SJ, Chang D, Kiat H, Klupp NL, Liu JP, Li X. Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2009, (4):CD006690. CD006690.pub2.
8. Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health 2011, 8(1):15-20. 3037057, 21318011.
9. Chen Z, Xia C, Wei Z. Clinical study of Jiangtang Xiaozhi capsule in treating type 2 diabetes mellitus patients. Chin J Integr Tradit Chin Med 2012, 32(7):910-913.
10. Ge Z, Jin L, Yan A, Dong X, Liu J, Liu J. Study of Jiangtang Xiaozhi on decreasing blood glucose in rat and mouse models of diabetes mellitus. Chin J Exp Tradit Med Formulae 2010, 16(16):143-416.
11. Twigg SMKM, Davis TM, Neylon EK, Flack JR. Prediabetes: a position statement from the australian diabetes society and australian diabetes educators association. Med J Australia 2007, 186(9):461-465.
12. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006, 295(14):1688-1697. 10.1001/jama.295.14.1688, 16609091.
13. Bender R, Lange S. Adjusting for multiple testing - when and how?. J Clin Epidemiol 2001, 54:343-349. 10.1016/S0895-4356(00)00314-0, 11297884.
14. Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 health survey 2000, Lincoln: Quality Metric Inc.
15. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21(12):2191-2192. 10.2337/diacare.21.12.2191, 9839117.
16. Emoto M, Nishizawa Y, Maekawa K, Yoshikazu H. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999, 22(5):818-822. 10.2337/diacare.22.5.818, 10332688.
17. Wallace TMLJC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6):1487-1495. 10.2337/diacare.27.6.1487, 15161807.
18. Hawthorne G, Osborne R, Taylor A, Sansoni J. The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. Qual Life Res 2007, 16(4):661-673. 10.1007/s11136-006-9154-4, 17268926.
19. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H. Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Evidence Report/Technology Assessment No. 128. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Pub. No 05-E026-2 2005, Rockville, MD: Agency for Healthcare Research and Quality.
20. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998, 35(1):34-40. 10.1007/s005920050098, 9625287.
21. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone Bad, and the glutathione connection. Diabetes 2003, 52(3):581-587. 10.2337/diabetes.52.3.581, 12606496.
22. Ramachandran B, Kandaswamy M, Narayanan V, Subramanian S. Insulin mimetic effects of macrocyclic binuclear oxovanadium complexes on streptozotocin-induced experimental diabetes in rats. Diabetes Obes Metab 2003, 5(6):455-461. 10.1046/j.1463-1326.2003.00302.x, 14617232.
23. Snehalatha C, Mary S, Selvam S, Sathish Kumar CK, Shetty SBA, Nanditha A, Ramachandran A. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the indian diabetes prevention programme-1 (IDPP-1). Diabetes Care 2009, 32(10):1796-1801. 10.2337/dc09-0676, 2752907, 19587369.
24. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008, 93(7):2559-2565. 10.1210/jc.2007-2404, 18397984.
25. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissén M, Isomaa B, Forsen B, Homström N, Saloranta C. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005, 54(1):166-174. 10.2337/diabetes.54.1.166, 15616025.
26. UKPDS Group U.K. Prospective diabetes study 16: overview of 6 years' therapy of type II diabetes, a progressive disease.(U.K. Prospective diabetes study group). Diabetes 1995, 44(11):1249. 1210, UKPDS Group.
27. Weyer CB, Mott CDM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104(6):787-794. 10.1172/JCI7231, 408438, 10491414.
28. Sung KRGK S. Utility off homeostasis model assessment of [beta]-cell function in predicting diabetes in 12,924 healthy koreans. Diabetes Care 2010, 33(1):200-202. 10.2337/dc09-1070, 2797973, 19808927.
29. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico city diabetes study. Diabetes Care 1996, 19(10):1138-1141. 10.2337/diacare.19.10.1138, 8886564.
30. Haffner SM, Gaskill HSP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995, 44:1386-1391. 10.2337/diabetes.44.12.1386, 7589843.
31. Kanauchi M, Nakajima M, Saito Y, Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism 2003, 52(4):476-481. 10.1053/meta.2003.50078, 12701062.
32. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the belfast diet study. Diabet Med 1998, 15(4):290-296. 10.1002/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M, 9585393.
33. Martens FMAC, Visseren FLJ, Lemay J, de Koning EJP, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002, 62(10):1463-1480. 10.2165/00003495-200262100-00004, 12093315.
34. Festa AMD, Hanley AJGP, Tracy RPP, D'Agostino RJP, Haffner SMMD. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. [Report]. Circulation 2003, 108(15):1822-1830. 10.1161/01.CIR.0000091339.70120.53, 14517163.
35. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297(5):499-508. 10.1001/jama.297.5.499, 17284700.
36. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003, 88(4):1637-1645. 10.1210/jc.2002-021786, 12679450.
37. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23(8):1296-1310. 10.1016/S0149-2918(01)80109-0, 11558866.